
|Articles|May 20, 2020
ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
3
IGS 2026: The expanding role of artificial intelligence in ophthalmology
4
Inner plexiform layer substrata: Possible biomarker of retinal health
5





























